Sweden - Health Indicators

See resource descriptions below for links to indicator metadata

Mortality and global health estimates: Infant mortality rate (between birth and 11 months per 1000 live births), Under-five mortality rate (per 1000 live births) (SDG 3.2.1), Maternal mortality ratio (per 100 000 live births), nMx - age-specific death rate between ages x and x+n, nqx - probability of dying between ages x and x+n, lx - number of people left alive at age x, ndx - number of people dying between ages x and x+n, nLx - person-years lived between ages x and x+n, Tx - person-years lived above age x, ex - expectation of life at age x, Number of deaths (see MORT_100), GBD - crude death rate, Neonatal mortality rate (0 to 27 days) per 1000 live births) (SDG 3.2.2), Adult mortality rate (probability of dying between 15 and 60 years per 1000 population), Distribution of years of life lost by major cause group, Age-standardized NCD mortality rate (per 100 000 population), Age-standardized DALYs (per 100,000), Number of deaths, Deaths per 1 000 live births, Distribution of causes of death among children aged < 5 years (%), Occupational risk factors attributable deaths, Occupational risk factors attributable DALYs ('000), Occupational risk factors attributable deaths per 100'000 capita, Occupational risk factors attributable DALYs per 100'000 capita, Stillbirth rate (per 1000 total births), Number of deaths among children under-five, Number of infant deaths (between birth and 11 months), Number of neonatal deaths (0 to 27 days), Life expectancy at age 60 (years), Number of deaths (see MORT_100), Deaths per 100 000 population, Projection of number of deaths, Projection of deaths per 100 000 population, Disability-adjusted life years (DALYs), Disability-adjusted life years (DALYs) (per 100 000 population), Years of healthy life lost due to disability (YLDs), Years of healthy life lost due to disability (YLDs) (per 100 000 population), Years of life lost from mortality (YLLs), Years of life lost from mortality (YLLs) (per 100 000 population), Number of maternal deaths, Mortality rate for 5-14 year-olds (probability of dying per 1000 children aged 5-14 years), Number of deaths among children ages 5 to 9 years, Mortality rate among children ages 5 to 9 years (per 1000 children aged 5), Number of deaths among children ages 10 to 14 years, Mortality rate among children ages 10 to 14 years (per 1000 children aged 10)

Sustainable development goals: Adolescent birth rate (per 1000 women), Births attended by skilled health personnel (%), Life expectancy at birth (years), Healthy life expectancy (HALE) at birth (years), Ambient and household air pollution attributable death rate (per 100 000 population), New HIV infections (per 1000 uninfected population), Malaria incidence (per 1 000 population at risk), Concentrations of fine particulate matter (PM2.5), Mortality rate attributed to unintentional poisoning (per 100 000 population), Age-standardized road traffic mortality (per 100 000 population), Prevalence of current tobacco use among persons aged 15 years and older (age-standardized rate), Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2), Reported number of people requiring interventions against NTDs, Out-of-pocket expenditure as a percentage of total expenditure on health (see GHED_OOPSCHE_SHA2011) (void SDGOOP), Estimated direct deaths from major conflicts (per 100 000 population), Average death rate due to natural disasters (per 100 000 population), Crude suicide rates (per 100 000 population), Skilled health professionals density (per 10 000 population), Average of 13 International Health Regulations core capacity scores, 1st version of the questionnaire, Healthy life expectancy (HALE) at age 60 (years), Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized), New HIV infections among adults 15-24 years old (per 1000 uninfected population), Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%), Average of 13 International Health Regulations core capacity scores, SPAR version, 1st edition, Girls aged 15 years old that received the recommended doses of HPV vaccine (%), Proportion of health facilities with a core set of relevant essential medicines available and affordable on a sustainable basis, Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month, Average of 15 International Health Regulations core capacity scores, SPAR version, 2nd edition

Millennium Development Goals (MDGs): Contraceptive prevalence (%), Prevalence of condom use by adults during higher-risk sex (15-49) (%), Deaths due to malaria (per 100 000 population) (see MALARIA_EST_MORTALITY) ( void MDG_0000000016), Deaths due to tuberculosis among HIV-positive people (per 100 000 population), Prevalence of HIV among adults aged >=15 years (per 100 000 population), Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%), Tuberculosis detection rate under DOTS (%), Tuberculosis treatment success under DOTS (%), Maternal mortality ratio (per 100 000 live births) - Country reported estimates, Contraceptive prevalence, among girls aged 15-19 (%), Unmet need for family planning, among girls aged 15-19 (%), Births attended by skilled health personnel, among girls aged 15-19 (%)

Health systems: Median availability of selected generic medicines (%) - Public, Median consumer price ratio of selected generic medicines - Public, Median availability of selected generic medicines (%) - Private, Antenatal care coverage - at least one visit (%), Median consumer price ratio of selected generic medicines - Private, Antenatal care coverage - at least four visits (%), Donor commitments (Million, constant 2009 US$), Commitments to recipient countries (Million, constant 2009 US$), Donor disbursements (Million, constant 2009 US$), Disbursements to recipient countries (Million, constant 2009 US$), Number of nursing personnel, Number of physicians, Number of midwifery personnel, Number of pharmacists, Number of pharmaceutical technicians/assistants, Number of community health workers, 2018, Number of traditional birth attendants, Number of radiographers, Number of other health workers, 2013, Number of dental technicians/assistants, Number of health management & support workers, Number of environment and public health workers (see HWF_0017) (void HRH), Number of laboratory scientists, Number of laboratory technicians/assistants, Number of dentists, Number of traditional medicine practitioners, Number of medical assistants, Number of personal care workers, Number of pharmaceutical personnel (see HWF_0015) (void HRH), Number of laboratory health workers, Number of dentistry personnel (see HWF_0011) (void HRH_21), Number of community and traditional health workers, Number of other health workers, 2018, Number of nursing and midwifery personnel (see HWF_0007) (void HRH), Pharmaceutical personnel density (per 1000 population), Physicians density (per 1000 population), Laboratory health workers density (per 1000 population), Dentistry personnel density (per 1000 population), Community and traditional health workers density (per 1000 population), Other health workers density (per 1000 population), Environmental and public health workers density (per 1000 population), Health management & support workers density (per 1000 population), Nursing and midwifery personnel density (per 1000 population), Radiotherapy units (per 1 000 000 population), Antenatal care coverage - at least one visit, among girls aged 15-19 (%), Total Pharmaceutical Expenditure (millions US$), Total Pharmaceutical Expenditure per capita (US$)rate), Share of Total Pharmaceutical Expenditure in Total Health Expenditure (%), Share of Public Pharmaceutical Expenditure in Total Pharmaceutical Expenditure (%), Public Pharmaceutical Expenditure per capita (US$), Density of pharmacists (per 10 000 population), Presence of National Medicines Policy, Presence of National Medicines Policy implementation plan, Right of access to essential medicines, Existence of formal Medicines Regulatory Authority, Website of the formal Medicines Regulatory Authority, Market Authorization for all pharmaceutical products required, Registration Fee pharmaceutical containing New Chemical Entity, Registration Fee generic pharmaceutical product, Inspectors are allowed to inspect premises where pharmaceutical activities are performed, Pharmaceutical manufacturers must comply with Good Manufacturing Practices, Licensing private pharmacies obligatory, National Quality Control Laboratory exists, Legal provisions control promoting and advertising of prescription medicine, Ban on Direct to Consumer Pharmaceutical Advertising, Legal provisions exist requiring authorization for conducting Clinical Trials by the MRA, Annual consumption of Morphine (mg/capita), National pharmacovigilance centre linked to the MRA exists, Children <5 years receive free medicines, Pregnant women receive free medicines, All medicines included in the EML, Social (health) fund is providing at least partial medicine coverage, System in place to monitor prices of medicines, Duties on imported active pharmaceutical ingredients, Duties on imported finished pharmaceutical products, Value Added Tax is levied on finished pharmaceuticals products, Public sector tender awards are publicly available, Availability of key medicines at the Central Medical Store in percentage (%), National Essential Medicine List exists, Standard Treatment Guidelines for common illnesses are made by Ministry of Health, National Standard Treatment Guidelines specific to paediatric conditions exist, National Medicines Information Center provides information on medicines, Existence of National strategy to contain antimicrobial resistance, Public sector, Private sector, Substitution of generic equivalents at the point of dispensing in public sector facilities is allowed, Substitution of generic equivalents at the point of dispensing in private sector facilities is allowed, For the pharmaceutical sector, Number of registered pharmaceutical products, Number of reports submitted in the last two year by the pharmacovigilance centre, Market share of domestic manufacturers (%), Market share of generic pharmaceuticals by value (%), Basis for NHA estimate, Population, Life Expectancy M, Life Expectancy F, Under 5 Mortality, Infant mortality, GDP, Gross domestic product per capita, NCD mortality rate, CVD and Diabetes mortality rate, Cancer mortality rate, TB mortality rate, Malaria mortality rate, HIV mortality rate, THE, THE per capita, Public Health Expenditure, Public Health Expenditure per capita, Public Health Expenditure as a % of Government Expenditure, Public Health Expenditure of a % of THE, Private Health Expenditure % of THE, OOP as a % of Private Health Expenditure, Premiums for private health plans as a % of private health expenditure, Population covered by private health insurance, Population covered by a public health service orr insurance plan, Total pharmaceutical expenditure, Share of total pharmaceutical expenditure in total health expenditure (%), Share of total pharmaceutical expenditure in gross domestic product (%), Total pharmaceutical expenditure per capita, Share of public pharmaceutical expenditures in total pharmaceutical expenditures (US$), Private TPE, Market share of generic pharmaceuticals by value (%), Pharmacists, Density of pharmacist (per 10.000), Presence of National Health Policy, NHP Implementation plan exists, Presence of national medicines policy, Presence of national medicines policy implementation plan, Pharmaceutical policy implementation is regularly monitored, Presence of National Clinical Laboratory Policy, NCLP implementation plan exists, Right of access to essential medicines, Presence of national good governance policy, Official guidelines on medicine donations exist, Policy to manage conflict of interest issues, Formal code of conduct for public officials, Whistle Blowing mechanism, Legal provision for granting patents on: Pharmaceuticals, Legal provision for granting patents on: Laboratory Supplies, Legal provision for granting patents on: Medical Supplies, Legal provision for granting patents on: Medical Equipment, TRIPS legislated through national legislation, Trasitional period eligibility, Compulsory Licensing, Bolar exemption, Parallel importing, Legal provisions related to: Data exclusivity, Legal provisions related to: Patent Extension, Legal provisions for the linkage between patent status and market authorization, Number of licensed pharmaceutical manufacturers, Manufacturing capacity: R&D new API, Manufacturing capacity: Production API, Manufacturing capacity: Production formulations, Manufacturing capacity: Repackaging of finished dose forms, Market share of domestic manufacturers by value (%), Market share of domestic manufactures by volume (%), Legal provisions for establishing MRA, Formal medicines regulatory authority exists, MRA part of MoH, MRA semi-autonomous, Medicines regulatory authority has it own website, MRA receives external technical assistance, MRA involved in harmonization / collaboration activities, Assessment of medicines regulatory system conducted in last 5 years, RA uses computerized information management system, Function of MRA: Market Authorization, Function of MRA: Inspection, Function of MRA: Import Control, Function of MRA: Licensing, Function of MRA: Market control, Function of MRA: Quality control, Function of MRA: Advertising, Function of MRA: Clinical trials, Function of MRA: Pharmacovigilance, Funding of MRA: Government, Funding of MRA: Fees for service, Funding of MRA: Other funding, Funding of MRA: Revenues derived from RA kept in RA, Market authorization for all pharmaceutical products is required, Mechnaisms for exceptions / waiver of registration, Mutual recognition, Public transparency of criteria for MA application assessment, WHO prequalification programme information used for product registration, Number of registered pharmaceuticals, List of pharmaceuticals with defined periodicity required to be publicly available, Medicines registration includes INN, Fee required for Marketing Authorization applications, Fee for pharmaceuticals containing new chemical entity, Registration fee generic pharmaceutical product, Legal provisions for the appointment of government pharmaceutical officials, Inspectors are allowed to inspect premises where pharmaceutical activities are performed, Inspection a pre-requisite for licensing of: Public, Inspection a pre-requisite for licensing of: Private, Inspection requirements the same for public and private facilities, Local manufacturers - GMP compliance, Private Wholesalers, Retail distributors, Public pharmacies and stores, Pharmacies and dispensing points of health facilities, Authorization to import medicines required, Sampling of imported products for testing permitted, Importation of medicines through authorized ports of entry, Inspection of pharmaceutical products at authorized ports of entry permitted, Pharmaceutical manufacturers must comply good manufacturing practices, Licensing required for: Manufacturers, Licensing required for: Importers, Licensing required for: Wholesalers, Licensing private pharmacies obligatory, Licensing required for: public pharmacies, Wholesalers and distributors to comply with Good Distribution Practices, Pharmacists to be registered, Good Manufacturing Practices (GMP) published, National Good Distribution Practice requirements published, National Good Pharmacy Practice Guidelines published, List of all licensed pharmaceutical facilities (publication legally required), Legislation supports Pharmaceutical market regulation, Quality control testing laboratory is available, Quality control laboratory is part of medication regulatory authority, Testing services contracted out by regulatory authority, For quality monitoring in public sector (pharmacy stores and health facilities), For quality monitoring in private sector (retail outlets), When there are complaints / problems, For product registration, For public procurement prequalification, For public program products prior to acceptance and/or distribution, Number of quality control samples tested in past two years, Number of samples that failed the testing in two years, Legal provisions control promoting and advertising of prescription medicine, Ban on direct to consumer pharmaceutical advertising, Pre-approval for medicines advertisements and promotional materials required, Guidelines for advertising and promotion of non-prescription medicines, Code of conduct for advertising by MA holders exists and is publicly available, Code of conduct applies to: Both, Voluntary adherence to code, Code contains formal process for complaints and sanctions, Up to date list of complaints and sanctions publicly available, Legal provisions exist requiring authorization for conducting clinical trials by the medical regulatory authority, Clinical Trials require ethics committee/institutional review board approval, Registration of clinical trials in international/national/regional registry, Single convention on narcotic drugs, 1961, The 1972 protocol amending the single convention on narcotic drugs, 1961, Convention on psychotropic substances, 1971, United nations convention against the illicit traffic in narcotic drugs and psychotropic substances, 1988, Laws for the control of narcotic and psychotropic substances, and precursors exist, Annual morphine consumption (mg/capita), PV activities legally established within MRA mandate, MA holders required to continuously monitor safety of products and report to MRA, Legal provisions for monitoring of ADR exist, National pharmacovigilance center linked to the medicines regulatory authority, Number of reports submitted in the last two years by the national pharmacovigilance center, NPC publishes ADR bulletin, No. of ADRs on database, Number of reports of adverse drug reactions submitted in the last two years by the national pharmacovigilance center, No. of ADRs submitted to Uppsala database, Patients who cannot afford them received free medicines, Children under 5 receive free medicines, Pregnant women receive free medicines, Elderly received free medicines, All essential medicines are free, Free medicines for any non communicable diseases, Free medicines for Malaria, Free medicines for TB, Free medicines for STD, Free medicines for HIV, Free vaccines for EPI, National or social health insurance providing at least partial medicines coverage, Providing medicines that are on the Essential Medicines List for inpatients, Providing medicines that are on the Essential Medicines List for outpatients, Private health insurance schemes provide medicines coverage, Private health insurance provides coverage for medicines which are on the EML, Co-payments/ fee requirements for consultations, Co-payments/ fee requirements for medicines, Medicine pricing regulations, Pricing provisions aimed at: Manufacturers, Pricing provisions aimed at: Wholesalers, Pricing provisions aimed at: Retailers, Duties on active pharmaceutical ingredients, Duties on finished pharmaceutical products, Value added taxes on pharmaceutical products, Duty rate on active pharmaceutical ingredients, Duty rate on finished pharmaceutical products, Value added taxes rate, Revenues from fees used to pay salaries of health workers, Public sector procurement is decentralized, Public sector procurement is decentralized and centralized, Public sector procurement is the reponsibility of procurement agency that is part of MOH, Public sector procurement is the reponsibility of procurement agency that is semi autonomous, Public sector procurement is the reponsibility of procurement agency that is autonomous, A government procurement agency procures all public goods, Public sector requests for tender documents are publicly available, Public sector awards are publicly available, Procurement is based on prequalification of suppliers, The government supply system department has a central medical store, There are national guidelines on Good Distribution Practices, There is a licensing authority that issues GDP licenses, The licensing authority accredits public distribution facilities, A list of GDP certified warehouses in the public sector exists, A list of GDP certified distributors in the public sector exists, Availability of key medicines at the central medical store, Legal provisions exist for licensing wholesales in private sector, Legal provisions exist for licensing distributors in private sector, A list of GDP certified wholsesalers in the private sector exists, A list of GDP certified distributors in the private sector exists, Core medical training includes: concept of EML, Core medical training includes: Use for STGS, Core medical training includes: Pharmacovigilance, Core medical training includes: Problem based pharmacotherapy, Mandatory continuing education that includes pharmaceutical issues is required for doctors, Mandatory continuing education that includes pharmaceutical issues is required for nurses, Mandatory continuing education that includes pharmaceutical issues is required for paramedical staff, Public sector generic prescribing is obligatory, Private sector generic prescribing is obligatory, Core pharmacist training includes: EML, Core pharmacist training includes: Use of STG, Core pharmacist training includes: drug information, Core pharmacist training includes: clinical pharmacology, Core pharmacist training includes: medicines supply management, Generic substitution permitted in public sector, Generic substitution permitted in private sector, Antibiotics are sometimes sold OTC without prescription, Injectables are sometimes sold OTC without prescription, National medicines information center exists, Public education campaigns on rational medicine use topics have been conducted in previous two years, A survey on rational medicine use has been conducted in the previous two years, A national committee exists to monitor and promote rational use of medicines, National strategy to contain antimicrobial resistance exists, Existence of a funded national intersectoral taskforce to coordinate the promotion of appropriate use of antimicrobials, A national reference lab has responsibility for coordinating epidemiological surveillance of AMR, Legal provisions exist to govern the licensing and prescribing practices of prescriber, Legal provisions exist to restrict dispensing by prescribers, Prescribers in the private sector dispense medicine, Regulations require hospitals to organize/develop DTCs, More than half of referral hospital have a DTC, More than half of general hospitals have a DTC, More than half of regions/provinces have a DTC, Average number of medicines prescribed per patient contact in public health facilities, Percentage of medicines in outpatient public health care facilities that are prescribed by INN name, Percentage of patients in outpatient public health care facilities receiving antibiotics, Percentage of patients in outpatient public health care facilities receiving injections, Percentage of medicines adequately labelled in public health facilities, Diarrhoea in children treated with ORS, Nurses sometimes prescribe prescription-only medicines, Pharmacists sometimes prescribe prescription-only medicines, Paramedics sometimes prescribe prescription-only medicines, Personnel with less than one month training sometimes prescribe prescription-only medicines, Legal provisions exist to govern dispensing practices of pharmaceutical personnel, Number of medicines on essential medicines list, Written process for selecting medicines on the EML, Written process is publicly available, Mechanism to align EML and STG, Standard treatment guidelines for common illnesses produced by the ministry of health, STG specific to primary care exists, STG specific to secondary care exists, National standard treatment guidelines for children, % of public health facilities with copy EML (mean), % of public health facilities with copy STG (mean), EML includes formulations specific for children, There are explicitly documented criteria for the selection of medicines on the EML, There is a formal committee for the selection of products on the EML, Conflict of interest declarations are required from members of national EML committee, National medicines formulary exists, % of medicines prescribed in outpatient public health care facilities that are on the EML, Mandatory continuing education that includes rational use of medicines is required for pharmacists, Share of public pharmaceutical expenditures in total pharmaceutical expenditures (%), AMR strategy has been updated in 2010 or later, Essential medicines list exists, General government expenditure on health as percentage of gross domestic product, Out-of-Pocket expenditure on health as percentage of total health expenditure??, Prepaid plans as percentage of total health expenditure?, Biomedical engineers density (per 10 000 population), Number of licensed qualified surgeons actively working, Number of licensed qualified obstetricians actively working, Number of licensed qualified anaesthesiologists actively working, Number of biomedical engineers, Biomedical technicians density (per 10 000 population), Number of biomedical technicians

Malaria: Children aged <5 years sleeping under insecticide-treated nets (%), Children aged <5 years with fever who received treatment with any antimalarial (%), Malaria - number of reported confirmed cases, Malaria - number of reported deaths, Estimated number of malaria cases (see MALARIA_EST_CASES), Estimated number of malaria deaths (see MALARIA_EST_DEATHS), Number of under-five deaths from malaria, Malaria incidence per 100 000 population, Estimated malaria mortality rate (per 100 000 population), Number of people protected from malaria by indoor residual spraying (IRS), Number of malaria suspects examined by rapid diagnostic test (RDT), Number of malaria positive cases by rapid diagnostic test (RDT), Estimated number of malaria cases, Number of suspected malaria cases, Number of malaria suspects examined by microscopy, Number of indigenous P. falciparum malaria cases, Number of indigenous P. vivax malaria cases, Number of imported malaria cases, Number of malaria positive cases by microscopy, Estimated number of malaria deaths, Estimated malaria incidence (per 1000 population at risk), Total number of  malaria cases (presumed + confirmed cases), Number of confirmed malaria cases, Number of presumed malaria cases, Number of indigenous malaria cases, Population with access to an insecticide-treated bed net (ITN) for malaria protection (%), modelled, Number of malaria cases treated with any first  line tx courses (including artemisinin-based combination therapies (ACTs)), Number of malaria cases treated with artemisinin-based combination therapies (ACTs), Pregnant women attending antenatal care  at least once and receiving at least 3 doses of Intermittent Preventive Treatment of Malaria for Pregnant Women (IPTp3) (%), Status of indigenous malaria cases

Tuberculosis: Deaths due to tuberculosis among HIV-negative people (per 100 000 population), Incidence of tuberculosis (per 100 000 population per year), Prevalence of tuberculosis (per 100 000 population), Smear-positive tuberculosis case-detection rate (%), Smear-positive tuberculosis treatment-success rate (%), Tuberculosis treatment coverage, Number of deaths due to tuberculosis, excluding HIV, Number of prevalent tuberculosis cases, Number of incident tuberculosis cases, Incidence of tuberculosis (per 100 000 population) (HIV-positive cases), Number of incident tuberculosis cases, (HIV-positive cases), Tuberculosis - new and relapse cases (TB_c_newinc), Minimum legal drinking age, New cases: Pulmonary, smear-positive, New cases: pulmonary smear-negative, New cases: pulmonary smear unknown/not done, New cases: extrapulmonary, New cases: other, Relapse cases (pre-2013 definition), Retreatment cases: treatment after failure (pulmonary smear and/or culture positive), Retreatment cases: treatment after default (pulmonary smear and/or culture positive), Retreatment cases: other, Treatment history unknown, Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population), Laboratories providing tuberculosis diagnostic services using culture (per 5 million population), Laboratories providing drug susceptibility testing (DST) (per 5 million population), Second-line drug susceptibility testing (DST) available, Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases, Treatment success rate: previously treated TB cases, Tuberculosis - new and relapse cases, TB patients with known HIV status (%), Tested TB patients HIV-positive (%), HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%), HIV-positive TB patients on ART (antiretroviral therapy) (%), Estimated MDR-TB cases among notified pulmonary TB cases, New cases tested for RR-/MDR-TB (%), Previously treated cases tested for RR-/MDR-TB (%), Confirmed cases of MDR-TB, Confirmed cases of MDR-TB started treatment for MDR-TB (%), Treatment success rate for patients treated for MDR-TB (%), Total number of notified TB cases, Cases started on MDR-TB treatment, New or unknown treatment history cases: Pulmonary, clinically diagnosed, New or unknown treatment history cases: Pulmonary, bacteriologically confirmed, New cases: Pulmonary, smear-negative/unknown/not done and other new cases, Previously treated cases, excluding relapse, Relapse cases: Pulmonary, clinically diagnosed, Relapse cases: extrapulmonary, Relapse cases: Pulmonary, bacteriologically confirmed, Confirmed cases of RR-/MDR-TB, Treatment success rate: new TB cases, Treatment success rate: HIV-positive TB cases, Treatment success rate: XDR-TB cases, TB_new_snuoth, Tuberculosis effective treatment coverage (%), xxx, Number of incident tuberculosis cases in children aged 0 - 14, Estimated number of MDR/RR-TB incident cases

Child health: for deletion: (child stunting, see NUTSTUNTINGPREV), Low-birth-weight newborns (%), Infants exclusively breastfed for the first six months of life (%), for deletion: (child underweight, see NUTUNDERWEIGHTPREV), Children aged <5 years overweight (%), Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%), Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%), Hepatitis B (HepB3) immunization coverage among 1-year-olds (%), Neonates protected at birth against neonatal tetanus (PAB) (%), Hib (Hib3) immunization coverage among 1-year-olds (%), Children aged <5 years wasted for age (%), BCG immunization coverage among 1-year-olds (%), Polio (Pol3) immunization coverage among 1-year-olds (%), Postnatal care visit within two days of birth (in the three years preceding the survey) (%), Postnatal care visit within two days of birth (in the five years preceding the survey) (%), Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%), Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%), Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%), Pneumococcal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%), Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%), Low birth weight (in thousands), Low birth weight, prevalence (%)

Infectious diseases: Cholera - number of reported cases, Diphtheria - number of reported cases, Japanese encephalitis - number of reported cases, Pertussis - number of reported cases, Total tetanus - number of reported cases, Meningitis - number of reported cases, Poliomyelitis - number of reported cases, Yellow fever - number of reported cases, H5N1 influenza - number of reported cases, Plague - number of reported cases, Mumps - number of reported cases, Number of reported cases of tuberculosis (DOTS), Congenital Rubella Syndrome - number of reported cases, Neonatal tetanus - number of reported cases, Total rubella - number of reported cases, Measles - number of reported cases, Number of reported cases of cholera, Number of reported deaths from cholera, Cholera case fatality rate, Number of suspected meningitis deaths reported, Number of suspected meningitis cases reported, Number of meningitis epidemic districts, Estimated leptospirosis deaths (per 100 000 population), Estimated leptospirosis incidence (per 100 000 population), Years of healthy life lost to disability (YLDs) due to leptospirosis, Years of healthy life lost to disability (YLDs) (per 100 000 population) due to leptospirosis, Years of life lost (YLLs) due to leptospirosis, Years of life lost (YLLs) (per 100 000 population) due to leptospirosis, Disability-adjusted life years (DALYs) due to leptospirosis, Disability-adjusted life years (DALYs) (per 100 000 population) due to leptospirosis

Neglected Tropical Diseases: Number of new leprosy cases, New leprosy case detection rate per 1 000 000 population, Number of leprosy cases registered for treatment (prevalence), Leprosy registered prevalence rate per 1 000 000 population, Number of new leprosy cases with G2D, New leprosy cases with G2D rate per 1 000 000 population, Number of new leprosy cases among children (less than 15 years of age), Number of new leprosy cases with G2D among children (less than 15 years of age), Number of new leprosy cases among females, Status of endemicity of Taenia solium, Presence of porcine cysticercosis, Number of pigs in the country, Presence of roaming backyard pigs, New leprosy child case detection rate (less than 15 years of age) per 1 000 000 child population

World Health Statistics: Literacy rate among adults aged >= 15 years (%) (void WHS9_85), Population (in thousands) total, Net primary school enrolment ratio (%), Population median age (years), Population proportion under 15 (%), Population living on <$1 (PPP int. $) a day (%), Civil registration coverage of births (%), Population proportion over 60 (%), Gross national income per capita (PPP int. $), Civil registration coverage of causes of deaths (%), Total fertility rate (per woman), Population living in urban areas (%), Annual population growth rate (%), Antiretroviral therapy coverage among HIV-infected pregnant women for PMTCT (%), Hospital beds (per 10 000 population), Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%), Children aged <5 years with diarrhoea receiving ORT (%), Births by caesarean section (%), Number of dentistry personnel (see HWF_0011) (void WHS6_123), Children aged 6-59 months who received vitamin A supplementation (%) , 2015, Number of nursing and midwifery personnel (see HWF_0007) (void WHS6), Deaths due to HIV/AIDS (per 100 000 population), Number of community health workers, 2010, Dentistry personnel density (per 10 000 population), Nursing and midwifery personnel density (per 10 000 population), Community health workers density (per 10 000 population), Deaths due to malaria (per 100 000 population) (see MALARIA_EST_MORTALITY) ( void WHS2_152), Age-standardized mortality rate by cause (per 100 000 population) - Cancer, Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular, Distribution of causes of death among children aged <5 years (%) - Malaria, Distribution of causes of death among children aged <5 years (%) - Pneumonia, Distribution of causes of death among children aged <5 years (%) - Injuries, Distribution of causes of death among children aged <5 years (%) - Diarrhoea, Distribution of causes of death among children aged <5 years (%) - Measles, Distribution of causes of death among children aged <5 years (%) - HIV/AIDS, Distribution of causes of death among children aged <5 years (%) - Other diseases, Distribution of years of life lost by broader causes (%) - Injuries, Distribution of causes of death among children aged <5 years (%) - Prematurity, Distribution of causes of death among children aged <5 years (%) - Neonatal sepsis, Distribution of causes of death among children aged <5 years (%) - Congenital anomalies, Number of pharmaceutical personnel (see HWF_0015) (void WHS6), Number of environment and public health workers (see HWF_0017) (void WHS6), Density of pharmaceutical personnel (per 10 000 population), Density of environment and public health workers (per 10 000 population), Number of reported cases of tuberculosis, Distribution of causes of death among children aged <5 years (%) - Birth asphyxia, Children aged = 15 years (%) (void CCO_WHS9_85), Completeness of cause-of-death data (%), Official development assistance for medical research and basic health sectors as a percentage of GNI (%), by donor country, Total net official development assistance to medical research and basic health sectors per capita (US$), by recipient country, Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%)

Substance use and mental health: Fines for violations, Fines on the establishment, Fines on the patron, Dedicated funds for enforcement, Citizen complaints and investigations, Daily users of any smokeless tobacco product (crude rate), Current smokers of cigarettes (youth rate), Exposure to smoke at home, Exposure to smoke outside home, Access to a toll-free quit line (please see O_Quitline), Smoking cessation support is available in hospitals (see O_Avail_hosp), Smoking cessation support is available in health clinics or other primary care facilities (see O_Avail_hlth_clin), Smoking cessation support is available in offices of health professionals (see O_Avail_off_hlth_prof), Smoking cessation support is available in the community (see O_Avail_community), Smoking cessation support is available in other settings (see O_Avail_other), Nicotine replacement therapy - legally sold (see O_NRT_sold), Nicotine replacement therapy - place available (see O_NRT_where), Bupropion - legally sold (see O_Bup_sold), Bupropion - place available (see O_Bup_where), Varenicline - legally sold (see O_Varen_sold), Varenicline - place available (see O_Varen_where), Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging (see W2_pc_front_back_B), Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging (see W3_pc_front_B), Specific health warnings are mandated for other smoked tobacco packaging (see W15_specific_hw_B), Number of health warnings approved by the law for other smoked tobacco packaging (see W16_number_hw_B), Health warnings on other smoked tobacco packaging must be rotated (see W7_rotation_B), Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging (see W4_pc_back_B), Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale (see W11_outside_pack_B), Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health (see W14_harm_effects_B), Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging (see W6_font_B), Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country (see W8_princ_langs_B), Health warnings on other smoked tobacco packaging must include a photograph or graphic (see W10_graphic_B), Year of survey of youth (M_svy_yr_youth), Representativeness of youth survey (see M_svy_national_youth), Repeating interval for survey of youth (years), Alcohol, consumption of pure alcohol by type of beverage (%), Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average, Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010, Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol), Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol, Alcohol, tourist consumption (in litres of pure alcohol), Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol), Alcohol, abstainers lifetime (%), Abstainers (15-19 years), lifetime (%), Alcohol, abstainers past 12 months (%), Abstainers (15-19 years), past 12 months (%), Alcohol, consumers past 12 months (%), Alcohol, former drinkers (%), Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%), Alcohol, patterns of drinking score, Age-standardized DALYs, alcohol use disorders, per 100,000, Age-standardized DALYs, breast cancer, per 100,000, Age-standardized DALYs, colon and rectum cancers, per 100,000, Age-standardized DALYs, diabetes mellitus, per 100,000, Age-standardized DALYs, drownings, per 100,000, Age-standardized DALYs, falls, per 100,000, Age-standardized DALYs, fires, per 100,000, Age-standardized DALYs, ischaemic heart disease, per 100,000, Age-standardized DALYs, liver cancer, per 100,000, Age-standardized DALYs, liver cirrhosis, per 100,000, Age-standardized DALYs, mouth and oropharynx cancer, per 100,000, Age-standardized DALYs, oesophagus cancer, per 100,000, Age-standardized DALYs, poisoning, per 100,000, Age-standardized DALYs, prematurity and low birth rate, per 100,000, Age-standardized DALYs, road traffic accidents, per 100,000, Age-standardized DALYs, self-inflicted injury, per 100,000, Age-standardized DALYs, other unintentional injuries, per 100,000, Age-standardized DALYs, violence, per 100,000, Age-standardized death rates, alcohol use disorders, per 100,000, Age-standardized death rates, breast cancer, per 100,000, Age-standardized death rates, colon and rectum cancers, per 100,000, Age-standardized death rates, diabetes mellitus, per 100,000, Age-standardized death rates, drownings, per 100,000, Age-standardized death rates, falls, per 100,000, Age-standardized death rates, fires, per 100,000, Age-standardized death rates, ischaemic heart disease, per 100,000, Age-standardized death rates, liver cancer, per 100,000, Age-standardized death rates, liver cirrhosis, per 100,000, Age-standardized death rates, mouth and oropharynx cancer, per 100,000, Age-standardized death rates, oesophagus cancer, per 100,000, Age-standardized death rates, poisoning, per 100,000, Age-standardized death rates, prematurity and low birth rate, per 100,000, Age-standardized death rates, road traffic accidents, per 100,000, Age-standardized death rates, self-inflicted injury, per 100,000, Age-standardized death rates, other unintentional injuries, per 100,000, Age-standardized death rates, violence, per 100,000, Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000, Liver cirrhosis, age-standardized death rates (15+), per 100,000 population, Age-standardized death rates (15+ years), poisoning, per 100,000, Road traffic injuries, age-standardized death rates (15+), per 100,000 population, Age-standardized death rates (15+ years), violence, per 100,000, Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI, Alcohol use disorders (15+), 12 month prevalence (%) with 95%, Alcoholic psychosis, incidence, per 100,000, Cautions and arrests for drink-driving, per 100,000 population, Hospital discharges, alcohol-related injuries and poisoning, per 100,000, Hospital discharges, alcoholic liver disease, per 100,000, Perceived trend in alcohol-related harm and consequences, Treatment admissions (inpatient), alcohol dependence, per 100,000, Treatment admissions (inpatient), alcoholic psychosis, per 100,000, Alcohol-related road traffic crashes, per 100,000 population, Alcohol-related road traffic crashes (% of all traffic crashes), Alcohol-related injury mortality, per 1,000, Alcohol-related disease mortality, per 100,000 (15+ years), Alcoholic excise tax revenue as a per cent of government revenue, Annual revenues from alcohol excise tax in millions US$, Alcohol expenditure as a per cent of total household expenditure, Social costs of alcohol use in millions US$, Adopted written national policy on alcohol, Alcoholic beverage legally defined, Alcohol use is banned, National legislation to prevent illegal alcohol, Advertising restrictions on national television, Advertising restrictions on cable television, Advertising restrictions on national radio, Advertising restrictions on local radio, Advertising restrictions in print media, Advertising restrictions at cinemas, Advertising restrictions on billboards, Advertising restrictions at point-of-sale, Advertising restrictions on the internet, Restrictions on product placement on national television, Restrictions on product placement on cable television, Age limits on-premise service, Legal blood alcohol concentration (BAC) limits, Random breath testing (RBT) use, Prices for alcoholic beverages (average, US$), Off-premise sales restrictions on days, Off-premise sales restrictions on hours, Off-premise sales restrictions on places, Off-premise sales restrictions on outlet density, Off-premise sales restrictions at specific events, Off-premise sales restrictions at petrol stations, On-premise sales restrictions on days, On-premise sales restrictions on hours, On-premise sales restrictions on places, On-premise sales restrictions on outlet density, On-premise sales restrictions at specific events, On-premise sales restrictions to intoxicated persons (archived), Restrictions on sponsorship of sporting events, Restrictions on sponsorship of youth events, Restrictions on sales promotion from producers (parties, events), Restrictions on sales promotion from retailers (sales below cost), Restrictions on sales promotion from owners of pubs and bars (alcohol for free), Government monopoly on production, Government monopoly on retail sales, Licence required for production, Licence required for retail sales, Excise tax as a per cent of the retail price of alcoholic beverages, Excise duty (average) per hectolitre in Euros, Excise tax as a per cent of the total retail price for 1 litre of pure alcohol, Duty paid or excise stamp on alcohol container, Excise tax on alcoholic beverages, Value-added tax (VAT) on alcohol (%), Restrictions on alcohol use in public places, Health warning labels on alcohol advertising, Health warning labels on alcohol containers, Monitoring, Treatment, services, Interventions, projects, training, Awareness activities, Information, education, prevention, Standard drink measures, in grams per unit, National drinking guidelines, 2010, Production in 1000s hectolitres, Imports in 1000s hectolitres, Sales of beer in 1000s hectolitres, Exports of beer (barley) in 1000s hectolitres, Perceived trend in production, Perceived trend in imports, Perceived trend in sales, Perceived trend in exports, Surveys, research, Counselling, Sales of wine in 1000s hectolitres, Sales of spirits in 1000s hectolitres, Exports of wine (grape) in 1000s hectolitres, Exports of spirits in 1000s hectolitres, Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2), Point prevalence (%), alcohol use disorders, 15+ years, Point prevalence (%), drug use disorders, 15+ years, Age-standardized death rates, alcohol and drug use disorders, per 100 000, Age-standardized DALYs, alcohol and drug use disorders, per 100 000, Psychoactive substance causing entry into treatment, Age-standardized DALYs, cerebrovascular disease, per 100,000, Age-standardized death rates, cerebrovascular disease, per 100,000, Epidemiological data collection system for substance use disorders, Service delivery data collection system for substance use disorders, National survey on substance use among children and adolescents, Data on substance use disorders disseminated in national annual reports, Substance use policy at the national level, Substance use policy at the national level, level of integration, Policy documents on the pharmacological treatment of substance use disorders, Guidelines on the pharmacological treatment of substance use disorders, Legislative provision for treatment and rehabilitation of substance use disorders, Legislative provision for compulsory treatment, Drug courts, Programmes diverting clients from the justice system towards treatment, Confidentiality of health records on substance use disorders protected by law, Government unit for substance use disorder treatment, Budget line for substance use disorder treatment, Financing method for substance use disorder treatment, Governement benefits for persons with substance use disorders, Government benefits for alcohol use disorders, subsidy or disability pension, Government benefits for drug use disorders, subsidy or disability pension, Sector for inpatient detoxification of alcohol use disorders, Sector for inpatient treatment of alcohol dependence, Sector for outpatient treatment of alcohol dependence, Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions, Sector for residential long-term rehabilitation of alcohol use disorders, Sector for inpatient detoxification of drug use disorders, Sector for inpatient treatment of drug dependence, Sector for outpatient treatment of drug dependence, Sector for substitution maintenance therapy of opioid dependence, Sector for residential long-term rehabilitation of drug use disorders, Treatment system for substance use disorders, Treatment setting for substance use disorders, most common, Specialized treatment services for drug use disoders and HIV/AIDS, Specialized treatment services for substance use disorders and TB, Open access services for substance use disorders, Treatment slots for alcohol and drug use disorders, outpatient, per 10 000, Beds for the treatment of substance use disorders, per 100 000, Length of stay for inpatient detoxification, days, Length of stay for inpatient short-term treatment, days, Length of stay for inpatient long-term residential treatment, days, Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance), Timeframe of opioid agonist treatment, Methadone used for the treatment of opioid dependence, Methadone used for detoxification or maintenance, Methadone formulation used for the treatment of opiod dependence, Buprenorphine used for the treatment of opioid dependence, Buprenorphine used for detoxification or maintenance, Buprenorphine/naloxone used for the treatment of opioid dependence, Buprenorphine/naloxone used for detoxification or maintenance, Methadone provision in clinical and community-based settings, Buprenorphine provision in clinical and community-based settings, Buprenorphine/naloxone provision in clinical and community-based settings, Supervision requirements for methadone administration, Supervision requirements for buprenorphine administration, Supervision requirements for buprenorphine/naloxone administration, Prescription requirements for methadone, Prescription requirements for buprenorphine, Prescription requirements for buprenorphine/naloxone, Commencement of treatment with opioid agonists, Pharmacotherapy used for the management of alcohol withdrawal, Pharmacotherapy used for the management of benzodiazepine withdrawal, Pharmacotherapy used for the management of cannabis withdrawal, Essential list of medicines, Essential list of medicines, pharmacotherapy for substance use disorders, Government unit for substance use disorder prevention, Budget line for substance use disorder prevention, Funding method for substance use disorder prevention, Prevention activities for substance use disorders, main focus, Programmes for the prevention of substance use disorders for special populations, Screening and brief interventions for substance use and substance use disorders, Harm reduction programmes for IDUs, Health professionals mostly involved in treatment of substance use disorders, Clinical supervision of health care staff, Standards of care for health professionals, Standards of care for health professionals, maintenance, Standards of care for health professionals, human rights, NGOs for alcohol use disorders, NGOs for drug use disorders, Self-help groups for substance use disorders, Groups and agencies for the prevention of substance use disorders, Mental health policy, Mental health plan, Stand-alone law for mental health, Government expenditures on mental health as a percentage of total government expenditures on health (%), Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%), Psychiatrists working in mental health sector (per 100 000 population), Nurses working in mental health sector (per 100 000 population), Social workers working in mental health sector (per 100 000 population), Psychologists working in mental health sector (per 100 000 population), Mental health outpatient facilities (per 100 000 population), Mental health day treatment facilities (per 100 000 population), Age-standardized suicide rates (per 100 000 population), Beds for mental health in general hospitals (per 100 000 population), Community residential facilities (per 100 000 population), Beds in community residential facilities (per 100 000 population), Beds in mental hospitals (per 100 000 population), Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance), Mental hospitals (per 100 000 population), Mental health units in general hospitals (per 100 000 population), Central coordinating entity for alcohol policy implementation, Framework of national alcohol policy, Level of adoption of national alcohol policy, Sectors represented in national alcohol policy, Cautions and arrests for public drunkenness, per 100,000 population, Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities), Adopted written national policy on alcohol, year adopted, Adopted written national policy on alcohol, year revised, Age limits off-premise sales, Consumer information on alcohol and health at points of sale, Educational programmes involving target groups in school curriculum, Brief interventions as health promotion/disease prevention, Server training on a regular basis, Data collection on alcohol-related health indicators, System for monitoring alcohol-related harm, National treatment policy for alcohol use disorders, Persons with alcohol use disorders receiving treatment (%), Designation of alcohol tax revenues to health services, National surveys on drink-driving, Public-funded alcohol research/monitoring programmes, Public funds designated for alcohol research/monitoring programmes, in Euros, Community-based interventions/projects involving stakeholders, Interventions/projects actively involving young people and civil society, Training in screening and brief interventions for alcohol problems, Counselling to children in families with alcohol problems, Counselling to pregnant women with alcohol problems, Prevention/counselling at workplaces for those with alcohol problems, Year of latest adult prevalence survey, Name of survey of adults, Representativeness of survey of adults, Adult survey age range, Adult indicator 1 definition, Adult indicator 1 rate, Adult indicator 2 definition, Adult indicator 2 rate, Year of survey of adults - smokeless, Name of survey of adults - smokeless, Representativeness of survey of adults - smokeless, Adult survey age range - smokeless, Adult smokeless tobacco use indicator definition, Adult smokeless tobacco use indicator rate, Year of youth survey, Name of survey of youth, Representativeness of youth survey, Youth survey age range, Youth indicator 1 definition, Youth indicator 1 rate, Youth indicator 2 definition, Youth indicator 2 rate, Year of survey of youth - smokeless, Name of survey of youth - smokeless, Representativeness of survey of youth - smokeless, Youth survey age range - smokeless, Youth smokeless tobacco use indicator definition, Youth smokeless tobacco use indicator rate, Compliance with regulations on smoke-free environments (national legislation), Treatment for tobacco dependence available in health clinics or other primary care facilities, Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark (see W21_emissions_quant_A), Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited)., Ban on sale of smokeless tobacco products, Process evaluation was employed to assess implementation, Ban on advertising: Point of sale, Compliance with bans on direct advertising, Appearance of tobacco products in TV and/or films, Sponsored events, Compliance with bans on promotion and sponsorship, Ban on tobacco companies/tobacco industry publicizing their “Corporate Social Responsibility” activities, Ban on entities other than tobacco companies/tobacco industry publicizing the Corporate Social Responsibility� activities of the tobacco companies, Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images (see E14b_movies_anti_tob_ads), Complete ban on tobacco vending machines, Subnational bans on tobacco advertising, promotion and sponsorship, Comprehensive bans in place subnationally, Action Plan for implementation of alcohol policy, Advertising restrictions on social media, Restrictions on product placement in films/movies, Importance of measures for enhancing compliance with age limits, Penalties for drink driving, Sobriety checkpoints, Price measures, New types of alcoholic beverages emerging, Level of taxation adjusted for inflation, Consumer information about calories, additives, etc on containers, Number of standard alcoholic drinks displayed on containers, Alcohol content displayed on containers, Government support for community action, Community-based interventions involving stakeholders, National guidelines for implementing effective community-based interventions, National alcohol policy specifically involves young people activities, Detection of marketing infringements, Penalties for marketing infringements, Alcohol, regional per capita (15+) consumption (in litres of pure alcohol), Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI, Alcohol-attributable Years of Life Lost (YLL) score, Alcohol-attributable fractions (15+), liver cirrhosis deaths (%), Alcohol-attributable fractions (15+), road traffic crash deaths (%), Alcohol-attributable fractions, all-cause deaths (%), Alcohol, regional prevalence of alcohol dependence (%), Alcohol, regional prevalence of alcohol use disorders (%), Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025, Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI, 2010 ( already in archive), Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI, Alcohol, average daily intake in grams among drinkers with 95%CI, Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016, Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI, 15-19 years old heavy episodic drinkers (population), % with 95%CI, 15-19 years old heavy episodic drinkers (drinkers only), %, 15-19 years old abstainers, lifetime (%), 15-19 years old former drinkers (%), 15-19 years old, current drinkers (%), National guidelines for the prevention and reduction of alcohol-related harm in schools, National guidelines for alcohol problem prevention and counselling at workplaces, Workplace representatives nationally involved to prevent and address alcohol-related harm, Server training, Legal obligation for schools to include alcohol use prevention, Legal obligation for schools to interact with parents regarding education and well-being, Legislation on alcohol testing at workplaces, Standard drink defined, National systems for monitoring alcohol consumption and harms, Regular reports from national monitoring systems, Comprehensive and regular reporting of alcohol situation, Clinical guidelines for brief interventions, National surveys on adult alcohol consumption, National surveys on youth alcohol consumption, National surveys on heavy espisodic drinking, Data collection on Foetal Alcohol Syndome, Data collected on harm from alcohol at workplace, 15-19 years old total alcohol consumption in litres of pure alcohol, Level of enforcement of BAC limits, 15-years old any alcoholic beverage consumed in past 12 months, (%), 15-years old first drink at 13 years or younger, (%), 15-years old any alcoholic beverage consumed in past 30 days, (%), 15-years old, any alcoholic beverage consumed at least once a week, (%), 13-15-years old any alcoholic beverage consumed in past 30 days, (%), 13-15-years old first drink before age 14, (%), Mental hospital admissions (per 100 000 population), Outpatient visits (per 100 000 population), Total workforce in mental health sector (per 100 000 population), Occupational therapists in mental health sector (per 100 000 population), Other non-specialized doctors in mental health sector (per 100 000 population), Mental health units in general hospitals admissions (per 100 000 population), Stand-alone policy or plan for mental health, Law requires fines for violations of direct advertising bans, 2015, Law requires fines for violations of indirect advertising bans,2015, Ban on display of tobacco products at points of sale, Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place, Compliance of ban on smoking in HEALTH-CARE FACILITIES, Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES, Compliance of ban on smoking in UNIVERSITIES, Compliance of ban on smoking in GOVERNMENT FACILITIES, Compliance of ban on smoking in INDOOR OFFICES, Compliance of ban on smoking in RESTAURANTS, Compliance of ban on smoking in PUBS AND BARS, Compliance of ban on smoking in PUBLIC TRANSPORT, Compliance of ban on advertising on national TV and radio, Compliance of ban on advertising on local magazines and newspapers, Compliance of ban on advertising on billboards and outdoor advertising, Compliance of ban on advertising at point of sale, Compliance of ban on free distribution of tobacco products in the mail or through other means, Compliance of ban on promotional discounts, Compliance of ban on non-tobacco goods AND services identified with tobacco brand names, Compliance of ban on brand name of non-tobacco products used for tobacco product, Compliance of ban on appearance of tobacco brands in TV and/or films (product placement), Compliance of ban on appearance of tobacco products in TV and/or films, Compliance of ban on sponsored events, Ban on Corporate Social Responsibility activities (CSR) (see E17a_csr_ban), Daily tobacco smoking, crude adjusted, Daily cigarette smoking, crude adjusted, Current tobacco smoking, crude adjusted, Current cigarette smoking, crude adjusted, Law requires fines for violations of indirect advertising bans,2018, Subnational laws or regulations exist banning some or all types of tobacco advertising, promotion and sponsorship, Law requires fines for violations of direct advertising bans, 2018, Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI, National legislation to prevent illegal alcohol sales, Cancer, age-standardized death rates (15+), per 100,000 population, Alcohol-attributable fractions (15+), cancer deaths, Heavy episodic drinking (youth 15 -19 years) past 30 days (%), Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%), Alcohol, tourist consumption (in litres of pure alcohol) (three-year average), Regional prevalence, AAFs (15+), liver cirrhosis deaths (%), Regional prevalence, AAFs (15+), road traffic crash deaths (%), Regional prevalence, AAFs (15+), cancer, Regional prevalence, AAFs ,all-cause deaths (%), Year the law was enacted (latest revision), Publication year of the policy or plan (latest revision)

Injuries and violence: Income level, Number of registered vehicles, Estimated number of road traffic deaths, Estimated road traffic death rate (per 100 000 population), Existence of a national drink-driving law, Attribution of road traffic deaths to alcohol (%), Existence of a national seat-belt law, Applicability of seat-belt law to all occupants, Existence of a national child-restraint law, Existence of national speed limits, Existence of a road safety lead agency, Existence of a national road safety strategy, Availability of funding for national road safety strategy, Existence of a formal pre-hospital care system, Definition of drink-driving by BAC, Distribution of road traffic deaths by type of road user (%), Blood Alcohol Concentration (BAC) limit for drivers, Seat-belt wearing rate (%), Applicability of national motorcycle helmet law to all occupants, Existence of a universal access telephone number for pre-hospital care, Maximum speed limits, Gross national income per capita (Atlas method), Population, Intimate partner violence prevalence among ever partnered women (%), Non-partner sexual violence prevalence (%), Child maltreatment: Extent of implementation of home-visiting programmes, Youth violence: Extent of implementation of life-skills and social development programmes, Intimate partner violence: Extent of implementation of dating violence prevention programmes, Elder abuse: Extent of implementation of caregiver-support programmes, Extent of implementation of mental health services for victims of all types of violence, Extent of implementation of child protection services, Extent of implementation of medico-legal services for victims of sexual violence, Lifetime prevalence of child physical abuse (%), Lifetime prevalence of child emotional abuse (%), Lifetime prevalence of child sexual abuse (%), Lifetime prevalence of child physical neglect (%), Estimates of number of homicides, Estimates of rates of homicides per 100 000 population, Physical fighting, past 12 months (%), Bullied, past 30 days (%), Law requires helmet to be fastened, Vehicle standards, Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months, Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in their lifetime

HIV/AIDS and other STIs: Prevalence of HIV among adults aged 15 to 49 (%), Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%), Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines, Estimated number of people (all ages) living with HIV, Number of adults aged 15 and over living with HIV, Number of deaths due to HIV/AIDS, Testing and counselling facilities, reported number, Testing and counselling facilities, estimated number per 100 000 adult population, Reported number of people receiving antiretroviral therapy, Reported number of children receiving antiretroviral therapy, Reported number of children receiving antiretroviral therapy, month and year of report, Number of pregnant women living with HIV who received antiretrovirals (excluding single dose Nevirapine) for preventing mother-to-child transmission, Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission, reporting period, Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission, Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods, Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines, Estimated number of children needing antiretroviral therapy based on WHO methods, Estimated antiretroviral therapy coverage among children, Testing and counselling facilities, reporting period, Women accessing antenatal care (ANC) services who were tested for syphilis (%), Antenatal care attendees who were positive for syphilis (%), Sex workers with active syphilis (%), Men who have sex with men (MSM) with active syphilis (%), Number of new HIV infections, Antenatal care attendees positive for syphilis who received treatment (%), Estimated antiretroviral therapy coverage among people living with HIV (%), Congenital syphilis number of reported cases, Congenital syphilis rate per 100 000 live births, Reported number of tests performed where results were received by a person (testing volume), Estimated number of tests performed where results were received by a person (testing volume), estimated number per 1000 population, Reported number of tests performed where results were received by a person (testing volume), reporting period

Public health and environment: Population using solid fuels (%), Percentage of the children under 15 years with blood lead levels above 5ug/dl, Percentage of the children under 15 years with blood lead levels above 10ug/dl, Percentage of the adults (15+ years) with blood lead levels above 5ug/dl, Percentage of the adults (15+ years) with blood lead levels above 10ug/dl, Lead attributable deaths, Lead attributable DALYs ('000), Lead attributable deaths per 100'000 capita, Lead attributable DALYs per 100'000 capita, Lead attributable DALYs ('000) in children under 5 years, Lead attributable DALYs per 100'000 children under 5 years, Percentage of children under 15 years exposed to second-hand smoke, Percentage of women (15+ years) exposed to second-hand smoke, Percentage of men (15+ years) exposed to second-hand smoke, Second-hand smoke attributable deaths, Second-hand smoke attributable DALYs ('000), Second-hand smoke attributable deaths per 100'000 capita, Second-hand smoke attributable DALYs per 100'000 capita, Second-hand smoke attributable deaths ('000) in children under 5 years, Second-hand smoke attributable deaths per 100'000 children under 5 years, Second-hand smoke attributable DALYs ('000) in children under 5 years, Second-hand smoke attributable DALYs per 100'000 children under 5 years, SDG 3.9.2 WASH deaths, Water, sanitation and hygiene attributable deaths ('000) in children under 5 years, Water, sanitation and hygiene attributable deaths per 100'000 capita, Water, sanitation and hygiene attributable deaths per 100'000 children under 5 years, Water, sanitation and hygiene attributable DALYs ('000), Water, sanitation and hygiene attributable DALYs ('000) in children under 5 years, Water, sanitation and hygiene attributable DALYs per 100'000 capita, Water, sanitation and hygiene attributable DALYs per 100'000 children under 5 years, Ambient air pollution attributable deaths (please see AIR_41), Ambient air pollution (Annual PM10 [ug/m3]), Ambient air pollution attributable deaths in children under 5 years, Ambient air pollution attributable death rate (per 100 000 population), Ambient air pollution attributable deaths per 100'000 children under 5 years, Ambient air pollution attributable DALYs, Ambient air pollution attributable DALYs in children under 5 years, Ambient air pollution attributable DALYs (per 100 000 population), Ambient air pollution attributable DALYs per 100'000 children under 5 years, Household air pollution attributable deaths, Household air pollution attributable deaths in children under 5 years, Household air pollution attributable deaths per 100'000 capita, Household air pollution attributable deaths per 100'000 children under 5 years, Household air pollution attributable DALYs, Household air pollution attributable DALYs in children under 5 years, Household air pollution attributable DALYs (per 100 000 population), Household air pollution attributable DALYs per 100'000 children under 5 years, Population using clean fuels and technologies (sum of)(%), Population using solid fuels (sum of) (%), Climate change attributable deaths, Climate change attributable DALYs ('000), Climate change attributable deaths per 100'000 capita, Climate change attributable DALYs per 100'000 capita, Climate change attributable deaths ('000) in children under 5 years, Climate change attributable deaths per 100'000 children under 5 years, Climate change attributable DALYs ('000) in children under 5 years, Climate change attributable DALYs per 100'000 children under 5 years, Deaths attributable to the environment, Age-standardized deaths attributable to the environment (per 100 000 population), Disability-adjusted life years (DALYs) attributable to the environment, Age-standardized DALYs attributable to the environment (per 100 000 population), Deaths attributable to the environment (%), Disability-adjusted life years (DALYs) attributable to the environment (%), Total environment attributable deaths ('000) in children under 5 years, Total environment attributable deaths per 100'000 children under 5 years, Total environment attributable DALYs ('000) in children under 5 years, Total environment attributable DALYs per 100'000 children under 5 years, Deaths attributable to the environment in children under 5 years (%), DALYs attributable to the environment in children under 5 years (%), UV radiation, UV radiation attributable deaths, UV radiation attributable DALYs ('000), UV radiation attributable deaths per 100'000 capita, UV radiation attributable DALYs per 100'000 capita, Occupational airborne particulates attributable deaths, Occupational airborne particulates attributable DALYs ('000), Occupational airborne particulates attributable deaths per 100'000 capita, Occupational airborne particulates attributable DALYs per 100'000 capita, Occupational carcinogens attributable deaths, Occupational carcinogens attributable DALYs ('000), Occupational carcinogens attributable deaths per 100'000 capita, Occupational carcinogens attributable DALYs per 100'000 capita, Occupational noise attributable DALYs ('000), Occupational noise attributable DALYs per 100'000 capita, Occupational ergonomic stressors attributable deaths, Occupational ergonomic stressors attributable DALYs ('000), Occupational ergonomic stressors attributable deaths per 100'000 capita, Occupational ergonomic stressors attributable DALYs per 100'000 capita, Occupational injuries attributable deaths, Occupational injuries attributable DALYs ('000), Occupational injuries attributable deaths per 100'000 capita, Occupational injuries attributable DALYs per 100'000 capita, Handwashing with soap after cleaning child's stool (%), Handwashing with soap after using the toilet (%), Ambient air pollution in urban areas (Annual PM10 [μg/m3]), Percent of urban inhabitants living in cities covered by PM measurements, Ambient air pollution in urban areas (Annual PM2.5 [μg/m3]), Joint effects of air pollution attributable deaths, Joint effects of air pollution attributable deaths in children under 5 years, Existence of national regulation, Year of national implementation of regulation, Access restrictions, Restriction and inspection of facilities, Information requirements, Training requirements, Safety requirements, Ambient air pollution attributable deaths, Ambient air pollution attributable death rate (per 100 000 population, age-standardized), Ambient air pollution attributable DALYs (please see AIR_7), DALYs attributable to ambient air pollution (age-standardized), Ambient air pollution attributable YLLs, Ambient air pollution attributable deaths (per 100 000 population, age-standardized), Existence of subnational regulation, Ambient air pollution attributable DALYs (per 100 000 population, age-standardized), Household air pollution attributable death rate (per 100 000 population), Household air pollution attributable death rate (per 100 000 population, age-standardized), Total environment attributable deaths in children under 5 years, Total environment attributable DALYs in children under 5 years, Population using safely managed drinking-water services (%), Population using at least basic drinking-water services (%), Population using safely managed sanitation services (%), Population using at least basic sanitation services (%), Population with basic handwashing facilities at home (%), Population practising open defecation (%), Household and ambient air pollution attributable DALYs ('000), Household and ambient air pollution attributable DALYs (per 100 000 capita), Household and ambient air pollution attributable DALYs (per 100 000 capita, age-standardized), Household and ambient air pollution attributable DALYs in children under 5 years ('000), Household air pollution attributable DALYs (per 100 000, age-standardized), Number of diarrhoea deaths from inadequate water, sanitation and hygiene, Number of diarrhoea deaths from inadequate water, Attributable fraction of diarrhoea to inadequate water, Number of diarrhoea DALYs from inadequate water, Number of diarrhoea deaths from inadequate sanitation, Attributable fraction of diarrhoea to inadequate sanitation, Number of diarrhoea DALYs from inadequate sanitation, Number of diarrhoea deaths from inadequate hygiene, Attributable fraction of diarrhoea to inadequate hygiene, Number of diarrhoea DALYs from inadequate hygiene, Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene, Number of diarrhoea DALYs from inadequate water, sanitation and hygiene

Nutrition: Early initiation of breastfeeding (%), Exclusive breastfeeding under 6 months (%), Proportion of children aged 6-23 months who receive a minimum acceptable diet, NLIS: Early initiation of breastfeeding within 1 hour of birth (%), Prevalence of anaemia in children aged 6–59 months (%), Number of children aged 6–59 months with anaemia (thousands), Prevalence of anaemia in women of reproductive age (aged 15-49) (%), Number of women of reproductive age (aged 15-49 years) with anaemia (thousands), Prevalence of anaemia in non-pregnant women (aged 15-49) (%), Number of non-pregnant women (aged 15-49 years) with anaemia (thousands), Prevalence of anaemia in pregnant women (aged 15-49) (%), Number of pregnant women (aged 15-49 years) with anaemia (thousands)

Noncommunicable diseases: Prevalence of overweight among adults, BMI ≥ 25 (age-standardized estimate) (%), Prevalence of overweight among adults, BMI ≥ 25 (crude estimate) (%), Prevalence of obesity among adults, BMI ≥ 30 (age-standardized estimate) (%), Prevalence of obesity among adults, BMI ≥ 30 (crude estimate) (%), Mean BMI (kg/m²) (age-standardized estimate), Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%), Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%), Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate), Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate), Mean systolic blood pressure (crude estimate), Mean systolic blood pressure (age-standardized estimate), Total NCD Deaths (in thousands), Premature deaths due to noncommunicable diseases (NCD) as a proportion of all NCD deaths (%), Mean fasting blood glucose (mmol/l) (age-standardized estimate), Mean fasting blood glucose (mmol/l) (crude estimate), Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate), Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate), Mean BMI (kg/m²) (crude estimate), Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, Prevalence of insufficient physical activity among school going adolescents aged 11-17 (crude estimate), Prevalence of underweight among adults, BMI < 18.5 (age-standardized estimate) (%), Prevalence of underweight among adults, BMI +1 standard deviations above the median (age-standardized estimate) (%), Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%), Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%), Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (age-standardized estimate) (%), Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (age-standardized estimate) (%), Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%), Mean HDL cholesterol, age-standardized, Mean HDL cholesterol, crude, Mean total cholesterol, age-standardized, Mean total cholesterol, crude, Mean Non-HDL cholesterol, age-standardized, Mean Non-HDL cholesterol, crude, Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, age-standardized, Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, age-standardized, Prevalence of hypertension among adults aged 30-79 years, age-standardized, Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, age-standardized, Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, crude, Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, crude, Prevalence of hypertension among adults aged 30-79 years, crude, Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, crude

Noncommunicable diseases CCS: Existence of operational policy/strategy/action plan for cardiovascular diseases, Existence of operational policy/strategy/action plan for cancer, Existence of operational policy/strategy/action plan for diabetes, Existence of operational policy/strategy/action plan for chronic respiratory diseases, Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol, Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs, Existence of operational policy/strategy/action plan to reduce physical inactivity, Existence of operational policy/strategy/action plan to decrease tobacco use, General availability of cervical cytology at the primary health care level, General availability of colon cancer screening at the primary health care level, General availability of breast cancer screening (by palpation or mammogram) at the primary health care level, General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level, General availability of total cholesterol measurement at the primary health care level, General availability of spirometry at the primary health care level, General availability of insulin in the public health sector, General availability of aspirin (100 mg) in the public health sector, General availability of metformin in the public health sector, General availability of thiazide diuretics in the public health sector, General availability of ACE inhibitors in the public health sector, General availability of CC blockers in the public health sector, General availability of statins in the public health sector, General availability of oral morphine in the public health sector, General availability of nicotine replacement therapy in the public health sector, General availability of steroid inhalers in the public health sector, Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach, Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets, Existence of population-based cancer registry, Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs, General availability of urine testing for albumin, General availability of bronchodilators in the public health sector, Existence of a national multisectoral commission, agency or mechanism for NCDs, Existence of a set of national NCD indicators and has set time-bound national targets for these indicators, Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors, Existence of any policies on marketing of foods to children, Existence of any policies to reduce population salt consumption, Existence of national policies on saturated fatty acids, Implementation of diet and/or physical activity public awareness program, General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level, General availability of diabetes testing (by HbA1c) at the primary health care level, Existence of a diabetes registry, Has a STEPS survey or a comprehensive health examination survey every 5 years, Existence of national screening program for breast cancer, Existence of national screening program for cervical cancer, Most widely used screening method in national cervical cancer screening program, Type of national cervical cancer screening program, Coverage of national cervical cancer screening program (%), Existence of national HPV vaccination programme, General availability of retinal photocoagulation in the public health system, General availability of dialysis in the public health system, General availability of renal replacement by transplantation in the public health system, General availability of coronary bypass or stenting in the public health system, General availability of thrombolytic therapy in the public health system, General availability of palliative care in primary health care in the public health system, General availability of palliative care in community or home-based care in the public health system, Availability of cardiovascular risk stratification in 50% or more primary health care facilities, Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities, Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities, General availability of beta blockers in the public health sector, General availability of sulphonylurea(s) in the public health sector, Existence of a set of time-bound national targets based on WHO guidance, Implementation of physical activity public awareness program, Existence of operational policy/strategy/action plan for oral health, Existence of a register of patients who had rheumatic fever and rheumatic heart disease, Has systems for follow-up/recall to deliver long-term penicillin prophylaxis to patients with rheumatic fever and rheumatic heart disease, Existence of tax on sugar-sweetened beverages, General availability of Angiotensin II receptor blockers (ARBs) in the public health sector, General availability of bone marrow transplantation in the public health system, Existence of national policies on trans-fatty acid elimination, Existence of national policies on saturated fatty acids / trans-fats, Existence of tax on foods high in fat, sugars or salt, Existence of price subsidies for healthy foods, Existence of tax incentives to promote physical activity, Existence of operational policy/strategy/action plan for eye health, Existence of operational policy/strategy/action plan for hearing health, Existence of operational policy/strategy/action plan to reduce overweight/obesity, Existence of national guidelines for physical activity, Implementation of a recent mass participation event, Implementation of a nutrition public awareness program, Existence of a national target on NCD mortality, Existence of a national target on alcohol, Existence of a national target on physical inactivity, Existence of a national target on salt, Existence of a national target on tobacco, Existence of a national target on blood pressure / hypertension, Existence of a national target on diabetes, Existence of a national target on obesity, Existence of a national target on drug therapy and counselling, Existence of a national target on essential medicines and technologies, Existence of population-based cancer registry, Has conducted a recent, national adult risk factor survey covering harmful alcohol use, Has conducted a recent, national adult risk factor survey covering tobacco use, Has conducted a recent, national adult risk factor survey covering unhealthy diet, Has conducted a recent, national adult risk factor survey covering physical inactivity, Has conducted a recent, national adult risk factor survey covering raised blood glucose/diabetes, Has conducted a recent, national adult risk factor survey covering raised total cholesterol, Has conducted a recent, national adult risk factor survey covering raised blood pressure/hypertension, Has conducted a recent, national adult risk factor survey covering salt/sodium intake, Has conducted a recent, national adult risk factor survey covering overweight and obesity, General availability of dilated fundus examination at the primary health care level, General availability of foot vibration perception by tuning fork at the primary health care level, General availability of urine strips for glucose and ketone measurement at the primary health care level, General availability of blood pressure measurement at the primary health care level, General availability of peak flow measurement at the primary health care level, General availability of Fixed dose combination avail (lisinopril + amlodipine) in the public health sector, General availability of Fixed dose combination avail (lisinopril + hydrochlorothiazide) in the public health sector, General availability of Fixed dose combination avail (telmisartan + amlodipine) in the public health sector, General availability of Fixed dose combination avail (telmisartan + hydrochlorothiazide) in the public health sector, General availability of combination budesonide formoterol inhaler in the public health sector, General availability of diabetic retinopathy screening in the public health system, General availability of alteplase for acute stroke management in the public health system, Existence of evidence-based national guidelines/protocols/standards for the management of cardiovascular diseases, Existence of evidence-based national guidelines/protocols/standards for the management of diabetes, Existence of evidence-based national guidelines/protocols/standards for the management of cancer, Existence of evidence-based national guidelines/protocols/standards for the management of chronic respiratory diseases, Existence of evidence-based national guidelines/protocols/standards for the management of alcohol use disorders, Existence of evidence-based national guidelines/protocols/standards for the management of tobacco dependence, Existence of evidence-based national guidelines/protocols/standards for the management of overweight/obesity, Existence of evidence-based national guidelines/protocols/standards for the management of physical inactivity, General availability of cancer centres or cancer departments at tertiary level in the public sector, General availability of pathology services (laboratories) in the public sector, General availability of cancer surgery in the public sector, General availability of chemotherapy in the public sector, General availability of radiotherapy in the public sector, Existence of national guidelines for physical activity for children under 5, Existence of national guidelines for physical activity for adults, Existence of national guidelines for physical activity for children and adolescents aged 5-19, Existence of national guidelines for physical activity for older adults, Existence of policy promoting physical activity: walking and cycling, Existence of policy promoting physical activity: workplace initiatives, Existence of policy promoting physical activity: active ageing, Existence of policy promoting physical activity: community-based and sports initiatives, Existence of policy promoting physical activity: public open spaces, Existence of policy promoting physical activity: childcare settings

Negelected tropical diseases: Number of new reported cases of Buruli ulcer, Dracunculiasis certification status of countries at the beginning of the year, Annual incidence of dracunculiasis cases, Number of new reported cases of human African trypanosomiasis (T.b. gambiense), Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense), Status of elimination of trachoma as a public health problem, Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem, Number of people who received treatment with antibiotics for trachoma, Number of people operated for trachomatous trichiasis, Status of endemicity of buruli ulcder

Essential health technologies: Availability of national standards or recommended lists of medical devices, Types of lists recommending health technology for high burden diseases, Type of nomenclature system, Use of nomenclature system, Health technology (medical device) national policy, Unit in the Ministry of Health responsible for the management of medical devices, Procurement of medical devices carried out at the national level, Availability of national list of approved medical devices for procurement or reimbursement, National guidelines, policies or recommendations on the procurement of medical devices, Availability of technical specifications of medical devices to support procurement or donations

Medical equipment: Total density per million population: Magnetic Resonance Imaging, Total density per million population: Computed tomography units, Total density per million population: Positron Emission tomography, Total density per million population: Gamma camera or Nuclear medicine, Total density per million population: Linear Accelerator, Total density per million population: Telecobalt Unit, Total density per million population: Radiotherapy units, Total density per million females aged from 50 to 69 years old: Mammography units

Demographic and socioeconomic statistics: Cellular subscribers (per 100 population), Most recent census (year), Number of cause-of-death registration years available, Number of national population surveys - child anthropometry, Number of national population surveys - child mortality, Number of national population surveys - maternal mortality, Number of national population surveys - HIV prevalence, Number of national population surveys - adult health, Civil registration coverage of cause-of-death (%), Ill-defined causes in cause-of-death registration (%), Poverty headcount ratio at $1.25 a day (PPP) (% of population), Human development index rank, Gender inequality index rank, ICT Development Index (IDI), ICT Development Index (IDI) rank, Percentage of individuals using the Internet, Mobile-cellular telephone subscriptions per 100 inhabitants

TOBACCO: Monitor, Protect from tobacco smoke, Offer help to quit tobacco use, Warn about the dangers of tobacco, Anti-tobacco mass media campaigns, Enforce bans on tobacco advertising, Raise taxes on tobacco, Estimate of current tobacco use prevalence (%), Estimate of daily tobacco use prevalence (%), Estimate of current cigarette smoking prevalence (%), Estimate of daily cigarette smoking prevalence (%), Smoke-free health-care facilities (national legislation), Smoke-free education facilities except universities (national legislation), Smoke-free universities (national legislation), Smoke-free government facilities (national legislation), Smoke-free indoor offices (national legislation), Smoke-free restaurants (national legislation), Smoke-free pubs, bars and cafés (national legislation), Smoke-free public transport (national legislation), Smoke-free other indoor public places (national legislation), Number of places smoke-free (national legislation), Fines for violations of smoke-free laws, Fines on the establishment for violations of smoke-free laws, Fines on the patrons of establishments for violations of smoke-free laws, Dedicated funds for enforcement of smoke-free laws, Citizen complaints and investigations of violations of smoke-free laws, Subnational smoke-free legislation authority exists, Access to a toll-free quit line, Smoking cessation support is available in hospitals, Smoking cessation support is cost-covered in hospitals, Smoking cessation support is available in offices of health professionals, Smoking cessation support is cost-covered in offices of health professionals, Smoking cessation support is available in the community, Smoking cessation support is cost-covered in the community, Smoking cessation support is available in other settings, Smoking cessation support is cost-covered in other settings, Nicotine replacement therapy - legally sold, Nicotine replacement therapy - place available, Nicotine replacement therapy - cost covered, Nicotine replacement therapy - on the Essential Medicines List, Bupropion - legally sold, Bupropion - place available, Bupropion - cost covered, Varenicline - legally sold, Varenicline - place available, Varenicline - cost covered, Law mandates that health warnings appear on cigarette packages, Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging, Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging, Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging, Specific health warnings are mandated for cigarette packaging, Number of health warnings approved by the law for cigarette packaging, Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale, Health warnings on cigarette packaging describe the harmful effects of tobacco use on health, Font style, font size and colour of health warnings are mandated for cigarette packaging, Health warnings on cigarette packaging must be rotated, Health warnings on cigarette packaging must be written in the principal language(s) of the country, Health warnings on cigarette packaging must include a photograph or graphic, Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package, Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry, Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale, Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps, Health warnings on cigarette packaging law requires or establishes fines for violations, Ban on deceitful terms on cigarette packaging, Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors, Cigarette packaging and labelling must not use descriptors depicting flavours, Cigarette packaging and labelling must display qualitative information on emission yields, Emission yields must be displayed on one or more principle display areas of cigarette packaging, Display of expiry dates is prevented on cigarette packaging, The quit line number must appear on cigarette packaging or labelling, Law mandates that health warnings appear on smokeless tobacco packages, Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging, Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging, Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging, Specific health warnings are mandated for smokeless tobacco packaging, Number of health warnings approved by the law for smokeless tobacco packaging, Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale, Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health, Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging, Health warnings on smokeless tobacco packaging must be rotated, Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country, Health warnings on smokeless tobacco packaging must include a photograph or graphic, Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package, Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry, Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale, Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps, Health warnings on smokeless tobacco packaging law requires or establishes fines for violations, Ban on deceitful terms on smokeless tobacco packaging, Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors, Smokeless tobacco packaging and labelling must not use descriptors depicting flavours, Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark, Smokeless tobacco packaging and labelling must display qualitative information on emission yields, Emission yields must be displayed on one or more principle display areas of smokeless tobacco packaging, Display of expiry dates is prevented on smokeless tobacco packaging, The quit line number must appear on smokeless tobacco packaging or labelling, At least one national mass media campaign ran during the survey period, Campaign was part of a comprehensive tobacco control programme, Campaign was pre-tested, Formative research was conducted prior to the campaign, Campaign ran on both national television and radio, Campaign utilized media planning, Earned media/public relations were used to promote the campaign, Outcome evaluation was employed to assess effectiveness of the campaign, Ban on advertising on national television and radio, Ban on advertising on international television and radio, Ban on advertising in local magazines and newspapers, Ban on advertising in international magazines and newspapers, Ban on billboard and outdoor advertising, Ban on advertising on the internet, Ban on free distribution in mail or through other means, Ban on promotional discounts, Ban on identifying non-tobacco products with tobacco brand names, Ban on use of brand name of non-tobacco product for tobacco product, Ban on appearance of tobacco brands in TV and/or films (product placement), Ban on tobacco companies funding or making contributions (including in-kind contributions) to smoking prevention media campaigns, including those directed at youth, Most sold brand of cigarettes - currency reported, Most sold brand of cigarettes - price in currency reported, Cheapest brand of cigarettes - currency reported, Most sold brand of cigarettes - taxes as a % of price - specific excise, Most sold brand of cigarettes - taxes as a % of price - ad valorem excise, Most sold brand of cigarettes - taxes as a % of price - import duties, Most sold brand of cigarettes - taxes as a % of price - value added tax, Most sold brand of cigarettes - taxes as a % of price - other taxes, Most sold brand of cigarettes - taxes as a % of price - total tax, Tobacco excises increased over the survey period, Average - taxes as a % of cigarette price - specific excise, Average - taxes as a % of cigarette price - ad valorem excise, Average - taxes as a % of cigarette price - import duties, Average - taxes as a % of cigarette price - value added tax, Average - taxes as a % of cigarette price - other taxes, Average - taxes as a % of cigarette price - total tax, Tobacco tax revenues - tobacco product types included, Tobacco tax revenues - year reported, Tobacco tax revenues - currency reported, Tobacco tax revenues - total excise (specific and ad valorem), Tobacco tax revenues - valued added tax (VAT) and other sales taxes, Tobacco tax revenues - import duties and all other taxes, Tobacco tax revenues - total revenues, Government objectives on tobacco control exist, National agency for tobacco control exists, Number of full-time equivalent staff in national agency, Annual budget for tobacco control in currency reported, National tobacco control budget - currency reported, Budget year, Smoking cessation support is available in health clinics or other primary care facilities, Smoking cessation support is cost-covered in health clinics or other primary care facilities, Law mandates that health warnings appear on other smoked tobacco packages, Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging, Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging, Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging, Specific health warnings are mandated for other smoked tobacco packaging, Number of health warnings approved by the law for other smoked tobacco packaging, Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale, Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health, Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging, Health warnings on other smoked tobacco packaging must be rotated, Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country, Health warnings on other smoked tobacco packaging must include a photograph or graphic, Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package, Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry, Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale, Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps, Health warnings on other smoked tobacco packaging law requires or establishes fines for violations, Ban on deceitful terms on other smoked tobacco packaging, Other smoked tobacco packaging and labelling must not use descriptors depicting flavours, Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark, Other smoked tobacco packaging and labelling must display qualitative information on emission yields, Emission yields must be displayed on one or more principle display areas of other smoked tobacco packaging, Display of expiry dates is prevented on other smoked tobacco packaging, The quit line number must appear on other smoked tobacco packaging or labelling, Ban on internet sales of tobacco products, Premium brand of cigarettes - currency reported, Premium brand of cigarettes - price in currency reported, Type of excise tax applied., Uniform excise tax applied Yes (Uniform), No (Tiered/varying rates), Greater reliance on specific tax in mixed excise regime, Minimum specific tax applied in ad valorem or mixed excise regime, Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT), Specific tax component automatically adjusted for inflation (or other), Tax administration: Tax stamps applied on tobacco products, Tax administration: Bans or limits on duty free imports by travellers, Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks), Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors, Tax structure: Excise tax proportion of price, Affordability - percentage of GDP per capita required to purchase 2000 cigarettes of the most sold brand, Price dispersion: Share of cheapest brand price in premium brand price (%) (the higher the % the smaller the gap), Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited), Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited), Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited), Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images, Ban on sponsorship (contributions and/or publicity of contributions), Ban on any form of contribution (financial or other support) to any event, activity or individual, Banning the publicity of financial or other sponsorship or support by the tobacco industry of events, activities, individuals, Ban on appearance of tobacco products in TV and/or films, Ban on product display at point of sale, Subnational smoking bans - at least one jurisdiction has a comprehensive ban in place, Cytisine - legally sold, Cytisine - place available, Cytisine - cost covered, Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark, Ban on advertising at point of sale, Ban on Corporate Social Responsibility activities (CSR), Ban on tobacco companies/the tobacco industry publicizing their CSR activities, Ban on entities other than tobacco companies/the tobacco industry publicizing the CSR activities of the tobacco companies/industry, Law requires fines for violations of advertising bans, Law requires fines for violations of promotion and sponsorship bans, Subnational bans on tobacco advertising, promotion and sponsorship authority exists, Ban on tobacco vending machines, Subnational bans on advertising, promotion and sponsorship - at least one jurisdiction has a comprehensive ban in place, Process evaluation was employed to assess implementation of the campaign, Cheapest brand of cigarettes - price in currency reported, A minimum price policy is implemented, Reported use of earmarked tobacco taxes, Tax stamps, fiscal marks, banderole or other types of marking are applied on cigarettes, Tax stamps, fiscal marks, banderole or other types of marking are applied on other tobacco products, Ban on sale of duty-free or excise-free cigarettes, Affordability – category of change 2010-2020 (Yes (less affordable), No (more affordable), No change)., Overall compliance with bans on direct advertising (score), Overall compliance with bans on promotion and sponsorship (score), Compliance with ban on advertising on national television and radio (score), Compliance with ban on advertising in local magazines and newspapers (score), Compliance with ban on billboard and outdoor advertising (score), Compliance with ban on advertising at point of sale (score), Compliance with ban on free distribution in mail or through other means (score), Compliance with ban on promotional discounts (score), Compliance with ban on use of brand name of non-tobacco product for tobacco product (score), Compliance with ban on indentifying non-tobacco products with tobacco brand names (score), Compliance with ban on appearance of tobacco brands in TV and/or films (score), Compliance with ban on appearance of tobacco products in TV and/or films (score), Compliance with ban on sponsorship (contributions and/or publicity of contributions) (score), Overall compliance with regulations on smoke-free environments (score), Compliance with smoke-free health-care facilities law (score), Compliance with smoke-free education facilities except universities law (score), Compliance with smoke-free universities law (score), Compliance with smoke-free government facilities law (score), Compliance with smoke-free indoor offices law (score), Compliance with smoke-free restaurants law (score), Compliance with smoke-free pubs and bars law (score), Compliance with smoke-free public transport law (score), Year of most recent survey of adults, Representativeness of most recent survey of adults, Age range of most recent survey of adults, Title of most recent survey of adults, Name of latest adult prevalence survey (nonsmoked), Year of latest adult prevalence survey (nonsmoked), Representation of latest adult prevalence survey (nonsmoked), Age range of latest adult prevalence survey (nonsmoked), Year of most recent adolescent survey, Representativeness of most recent adolescent survey, Age range of most recent adolescent survey, Title of most recent adolescent survey, Name of latest youth prevalence survey (nonsmoked), Year of latest youth prevalence survey (nonsmoked), Representation of latest youth prevalence survey (nonsmoked), Age range of latest youth prevalence survey (nonsmoked), Prevalence of current tobacco use among adolescents (%), Prevalence of daily tobacco use among adolescents (%), Prevalence of current tobacco smoking among adolescents (%), Prevalence of daily tobacco smoking among adolescents (%), Prevalence of current cigarette smoking among adolescents (%), Prevalence of daily cigarette smoking among adolescents (%), Prevalence of current smokeless tobacco use among adolescents (%), Prevalence of daily smokeless tobacco use among adolescents (%), Prevalence of current e-cigarette use among adolescents (%), Prevalence of daily e-cigarette use among adolescents (%), Prevalence of current tobacco use among adults (%), Prevalence of daily tobacco use among adults (%), Prevalence of current tobacco smoking among adults (%), Prevalence of daily tobacco smoking among adults (%), Prevalence of current cigarette smoking among adults (%), Prevalence of daily cigarette smoking among adults (%), Prevalence of current smokeless tobacco use among adults (%), Prevalence of daily smokeless tobacco use among adults (%), Prevalence of current e-cigarette use among adults (%), Prevalence of daily e-cigarette use among adults (%), Estimate of current tobacco smoking prevalence (%), Estimate of daily tobacco smoking prevalence (%), Estimate of current tobacco use prevalence (%) (age-standardized rate), Estimate of daily tobacco use prevalence (%) (age-standardized rate), Estimate of current tobacco smoking prevalence (%) (age-standardized rate), Estimate of daily tobacco smoking prevalence (%) (age-standardized rate), Estimate of current cigarette smoking prevalence (%) (age-standardized rate), Estimate of daily cigarette smoking prevalence (%) (age-standardized rate), Most sold brand of cigarettes - price in PPP$, Most sold brand of cigarettes - price in US$ at official exchange rates, Cheapest brand of cigarettes - price in US$ at official exchange rates, Cheapest brand of cigarettes - price in PPP$, Premium brand of cigarettes - price in US$ at official exchange rates, Premium brand of cigarettes - price in PPP$

Neglected tropical diseases: Status of yaws endemicity, Number of cases of yaws reported, Status of endemicity of cutaneous leishmaniasis, Status of endemicity of visceral leishmaniasis, Number of cases of cutaneous leishmaniasis reported, Number of cases of visceral leishmaniasis reported, Dracunculiasis cases, Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis, Reported number of individuals treated for onchocerciasis, Status of endemicity of onchocerciasis, Status of bejel endemicity, Status of pinta endemicity, Number of imported cases of cutaneous leishmaniasis reported, Number of imported cases of visceral leishmaniasis reported, Number of suspected yaws cases reported, Number of confirmed yaws cases reported

International Health Regulations (2005) monitoring framework: Legislation, Coordination, Surveillance, Response, Preparedness, Risk communication, Human resources, Laboratory, Points of entry, Zoonosis, Food safety, Chemical, Radionuclear

0: Electric field (kV/m), Alcohol-related road traffic crashes with fatalities, per 100,000 population, Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) (see W21_emissions_quant_B), Electric field (kV/m) low frequency, Alcohol-related crimes (% of all crimes), National drinking guidelines,2016, Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI, Food Safety (SPAR), Laboratory (SPAR), Surveillance (SPAR), Human Resources (SPAR), Risk Communication (SPAR), Points of Entry (SPAR), Care-seeking by type of patient and source of care (%) (see CARE_SOURCE), Care-seeking by type of patient and source of care (%)

Universal Health Coverage: Cataract surgical coverage of adults aged 50 and over (%), Effective cataract surgical coverage of adults aged 50 and over (%), Data availability for UHC index of service coverage (ranking), UHC Service Coverage Index (SDG 3.8.1), Index of Service Coverage (Actual), Primary data availability for UHC Service Coverage Index (SDG 3.8.1) (%), Tuberculosis detection and treatment, Prevalence of non-elevated blood pressure (%), Mean fasting plasma glucose, Surgeons (per 100 000), Prevalence of non-use of tobacco, Compliance with international health regulations, UHC Service Coverage sub-index on reproductive, maternal, newborn and child health, UHC Service Coverage sub-index on infectious diseases, UHC Service Coverage sub-index on noncommunicable diseases, UHC Service Coverage sub-index on service capacity and access

Global Observatory for eHealth (GOe): National universal health coverage strategy, strategy refers to the use of ICT to support UHC, National eHealth strategy, National eHealth strategy refers to objectives of UHC, National health information system (HIS) policy or strategy, Public funding for eHealth, Private funding for eHealth, Donor/ non-public development funding for eHealth, Public-private partnerships for eHealth, Strategy implementation funding available for eHealth, Proportion of public funding, Proportion of private funding, Proportion of donor/non public development funding, Proportion ofpublic private partnerships funding, Government-supported health internet sites provide information in multiple languages, Tertiary institutions provide students of health sciences with training on eHealth, Institutions offer in-service training to health professionals on ICT for health, mHealth programmes are sponsored by government, Regulating mobile devices and software, Promoting standards and interoperability, Providing guidance on privacy and security, Providing oversight and enforcement of data ownership, Promoting the development and adoption of mHealth, Regulatory oversight of mobile apps for quality, safety and reliability, Providing incentives and guidance for innovation research and evaluation of health, Government-sponsored mHealth programmes are being evaluated, Capacity, Infrastructure, Funding, Effectiveness, Cost-effectiveness, Demand, Legal, Policy, Priorities, Country has telehealth policy or strategy, Strategy includes objectives as to how telehealth contributes to UHC, Evaluation of any government-sponsored telehealth programmes, eLearning is used in pre-service education to teach health sciences students, Reducing cost of delivering content (pre-service), Improving access to content and experts (pre-service), Enabling access to education where learning facilities are limited (pre-service), Pre-service eLearning programmes have been evaluated, eLearning used for in-service training of health professionals, Reducing cost of delivering content (in-service), Improving access to content and experts (in-service), Enabling access to education where learning facilities are limited (in-service), eLearning courses accredited by continuing medical education or professional licensing bodies, eLearning programmes for in-service training of health professionals have been evaluated, Lack of capacity, Lack of infrastructure, Lack of funding, Not possible to gain a health sciences degree entirely through eLearning, Lack of evidence that eLearning is effective, Lack of evidence over cost-effectiveness, Lack of demand for eLearning programmes, Lack of suitable courses available, Insitutional educational policy does not include eLearning as an approach to teaching health sciences, Competing educational priorities, Country has national EHR, Country has specific legislation governing the use of national EHR system, Lack of capacity (for EHR), Lack of infrastructure (for EHR), Lack of funding (for EHR), lack of evidence showing effectiveness of EHR, Lack of evidence showing cost-effectiveness or EHR, Lack of demand by health professionals and patients, Lack of legislation or regulations covering use of EHR, National strategy does not promote the adoption of EHR, Lack of national or international standards for interoperability of EHR, Competing health system priorities, to define medical jurisdiction, liability or reimbursement of eHealth services such as telehealth, to address patient safety and quality of care based on data quality, data transmission standards, or clinical competency criteria, to protect privacy of personally identifiable data of individuals irrespective of whether it is paper or digital format, to protect the privacy of individuals' health-related data held in electronic format as an EHR, which governs the sharing of digital data between health professionals in other health services in the same country through the use of an EHR, which governs the sharing of digital data between health professionals in health services in other countries through the use of an EHR, which allows for the sharing of personal and health data between research entities, which allows individuals electronic access to their own health-related data when held in an EHR, which allows individuals to demand that their own data be corrected when held in an EHR if it is known to be inaccurate, which allows individuals to demand the deletion of health-related data from their EHR, Individuals have the legal right to specify which health-related data from their EHR can be shared with health professionals of their choice, Country has national policy or strategy on the use of social media by government organizations, Policy or strategy makes specific reference tothe use of social media in the health domain, Country has national policy or strategy regulating the use of big data in the health sector, Country has national policy or strategy regulating the use of big data by private companies, Effective standards and best practices for data capture not fully established, Insufficient incentives for data sharing, Capacity building required for new skills, Privacy and security laws need to be in place, Research into new analytical methods needs occur to meet the challenges of working with big data, Lack of integration between various health services

RSUD: GOVERNANCE, POLICY AND FINANCING : PREVENTION: Government unit/official responsible for prevention for substance use, Ministry/office that takes primary responsibility for prevention for substance use, Five years change in international cooperation for prevention for substance use

RSUD: GOVERNANCE, POLICY AND FINANCING: TREATMENT: Government unit/official responsible for treatment of substance use disorders, Ministry/office that takes primary responsibility for treatment of substance use disorders, Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for treatment of substance use disorders, Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for treatment of substance use disorders, Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for prevention for alcohol and drugs, Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for prevention for alcohol and drugs, Five years change in international cooperation for treatment of substance use disorders, Confidentiality of people in treatment for substance use disorders, Voluntary treatment for people with alcohol use disorders in the criminal justice system, Voluntary treatment for people with drug use disorders in the criminal justice system, Compulsory treatment for people with alcohol use disorders in the criminal justice system, Compulsory treatment for people with drug use disorders in the criminal justice system

RSUD: GOVERNANCE, POLICY AND FINANCING: FINANCING: Five-year change in government resources for prevention for substance use, Five-year change in government resources for treatment of substance use disorders, Financing methods for treatment for alcohol use disorders, Financing methods for treatment for drug use disorders, Hypothecated taxes to be spent on prevention and treatment for substance use disorders, Government benefits for people with alcohol use disorders, Government benefits for people with drug use disorders

RSUD: SERVICE ORGANIZATION AND DELIVERY: TREATMENT SECTORS AND PROVIDERS: Main sector for treatment for alcohol use disorders, Main sector for treatment for drug use disorders, Treatment programmes for children and adolescents with alcohol use disorders (treatment), Treatment programmes for children and adolescents with drug use disorders (treatment), Specialized treatment facilities for substance use disorders, Specialized treatment facilities for alcohol use disorders, Specialized treatment facilities for drug use disorders, Self-help groups

RSUD: SERVICE ORGANIZATION AND DELIVERY: TREATMENT CAPACITY AND TREATMENT COVERAGE: Main substance at treatment entry, Reported treatment coverage for substance dependence

RSUD: SERVICE ORGANIZATION AND DELIVERY: PHARMACOLOGICAL TREATMENT: Guidelines on pharmacological treatment for substance use disorders, Pharmacotherapy with methadone, Pharmacotherapy with buprenorphine, Pharmacotherapy with buprenorphine/naloxone, Access restrictions to maintenance treatment, Timeframe for maintenance treatment of opioid dependence, Registration of medications for alcohol dependence and withdrawal, Registration of medications for opioid dependence, Registration of medications for opioid withdrawal, Registration of naloxone for injection for opioid overdose, Availability of naloxone

RSUD: SERVICE ORGANIZATION AND DELIVERY: SCREENING AND BRIEF INTERVENTIONS: Screening and brief intervention for substance use in primary health care, Screening and brief intervention for substance use in antenatal services, Recommendations for screening and brief interventions for substance use in primary health care, Recommendations for screening and brief interventions for substance use in antenatal services

RSUD: SERVICE ORGANIZATION AND DELIVERY: PREVENTION PROGRAMS AND PROVIDERS: Groups and agencies involved in prevention programs, Prevention programmes for alcohol, Prevention programmes for specific populations for alcohol, Prevention programmes for drugs, Prevention programmes for specific populations for drugs

RSUD: SERVICE ORGANIZATION AND DELIVERY: SPECIAL PROGRAMMES AND SERVICES: HIV, Hepatitis counselling and treatment availability in specialized facilities and services, Programmes readily available, Standards of treatment and care for public specialized treatment facilities, Special treatment programmes for gambling disorder, Treatment programmes for women with alcohol use disorders, Treatment programmes for women with drug use disorders, Special housing services for alcohol use disorders, Special housing services for drug use disorders, Employment services for alcohol use disorders, Employment services for drug use disorders, Open access interventions for alcohol, Open access interventions for drugs

RSUD: HUMAN RESOURCES: Health professionals providing treatment for alcohol and drug use disorders, Standards of care for professionals providing treatment for alcohol and drug use disorders, Educational attainment in prevention, Postgraduate training programme in prevention, Continuing professional development in prevention, Educational attainment in treatment, Postgraduate training programme in treatment, Continuing professional development in treatment

RSUD: INFORMATION SYSTEMS: Epidemiological data collection for substance use, Service delivery data collection for substance use, Regular reports on epidemiological and service delivery data for substance use, System of monitoring alcohol involvement in forensic pathology, System of monitoring drugs involvement in forensic pathology, Epidemiological data collection system for substance use among children and adolescents (see RSUD_880)

RSUD: YOUTH: Epidemiological data collection system for substance use among children and adolescents, Treatment programmes for children and adolescents with alcohol use disorders (youth), Treatment programmes for children and adolescents with drug use disorders (youth)

FINANCIAL PROTECTION: Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, reported data) (%), Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, reported data) (%), Population pushed below the $1.90 a day poverty line by household health expenditures (%), Population pushed below the $3.20 a day poverty line by household health expenditures (%), Availability of estimates on large health expenditures as a share of total expenditure or income, Availability of estimates on impoverishment due to out-of-pocket health expenditures, Increase in poverty gap due to household health expenditures, expressed as a proportion of the $1.90 a day poverty line (%), Increase in poverty gap due to household health expenditures at the $1.90 a day poverty line, in cents of international dollars, Increase in poverty gap due to household health expenditures, expressed as a proportion of the $3.20 a day poverty line (%), Increase in poverty gap due to household health expenditures at the $3.20 a day poverty line, in cents of international dollars, Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, estimated data) (%), Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, estimated data) (millions), Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, estimated data) (%), Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, estimated data) (millions), Total population pushed below the $1.90 a day poverty line by household health expenditures (%), Total population pushed below the $1.90 a day poverty line by household health expenditures (millions), Total population pushed below the $3.20 a day poverty line by household health expenditures (%), Total population pushed below the $3.20 a day poverty line by household health expenditures (millions), Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%), Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions), Households with out-of-pocket payments greater than 40% of capacity to pay for health care (food, housing and utilities approach - developed by WHO/Europe) (%), Households pushed below or further below a relative poverty line (reflecting basic needs: food, housing, utilities) by out-of-pocket payments (%), Households impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%), Households further impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%), Population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%), Increase in poverty gap due to household health expenditures, expressed as a proportion of a relative poverty line (60% of median daily per capita consumption or income) (%), Population pushed further below the $1.90 a day poverty line by household health expenditures (%), Population pushed further below the $3.20 a day poverty line by household health expenditures (%), Population pushed further below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%), Total population pushed further below the $1.90 a day poverty line by household health expenditures (%), Total population pushed further below the $1.90 a day poverty line by household health expenditures (millions), Total population pushed further below the $3.20 a day poverty line by household health expenditures (%), Total population pushed further below the $3.20 a day poverty line by household health expenditures (millions), Total population pushed further below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%), Total population pushed further below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions)

Noncommunicable diseases and mental health: Number of deaths attributed to non-communicable diseases, by type of disease and sex, Number of suicide deaths

Health workforce: Medical doctors (per 10 000 population), Medical doctors (number), Generalist medical practitioners (number), Specialist medical practitioners (number), Medical doctors not further defined (number), Nursing and midwifery personnel (per 10 000 population), Nursing and midwifery personnel (number), Nursing personnel (number), Midwifery personnel (number), Dentists (per 10 000 population), Dentists (number), Dental Assistants and Therapists (number), Dental Prosthetic Technicians (number), Pharmacists (per 10 000 population), Pharmacists (number), Pharmaceutical Technicians and Assistants (number), Environmental and Occupational Health and Hygiene Professionals (number), Environmental and Occupational Health Inspectors and Associates (number), Medical and Pathology Laboratory scientists (number), Medical and Pathology Laboratory Technicians (number), Physiotherapists (number), Physiotherapy Technicians and Assistants (number), Traditional and Complementary Medicine Professionals (number), Community Health Workers (number), Medical doctors (%), Nursing personnel (%)

AMR GASP: Reporting countries, Proportion of isolates with resistance to azithromycin reported to WHO-GASP, Proportion of isolates with decreased susceptibility or resistance (DS/R) to cefixime reported to WHO-GASP, Proportion of isolates with resistance to ciprofloxacin reported to WHO-GASP, Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP, Proportion of isolates with decreased susceptibility or resistance (DS/R) to extended-spectrum cephalosporins reported to WHO-GASP, Number of isolates tested for azithromycin, Number of isolates tested for cefixime, Number of isolates tested for ciprofloxacin, Number of isolates tested for ceftriaxone, Number of isolates tested for extended-spectrum cephalosporins

ICD: ICD-11 implementation progress level

Immunization: Proportion of vaccination cards seen (%), Number of reported cases of poliomyelitis by wild poliovirus (WPV)

NLIS: Subclinical vitamin A deficiency in preschool-age children (serum/plasma retinol <0.70 μmol/L) (%), Clinical vitamin A deficiency in women (history of night blindness during most recent pregnancy) (%), Median urinary iodine concentration in children 6-12 years (μg/L), Any antenatal iron supplementation (%), Births in baby-friendly facilities (%), Population below the international poverty line (%), Nutrition Governance score, International Code on Marketing of Breast-milk Substitutes: Legal status of the Code, Maternity protection: Compliance with international labour standards, GDP per capita annual growth rate (%)

Cut down data for QuickCharts